

# Changming Xiong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1076489/publications.pdf>

Version: 2024-02-01

35  
papers

374  
citations

933447

10  
h-index

888059

17  
g-index

38  
all docs

38  
docs citations

38  
times ranked

452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart-Rate Recovery at 1 Min After Exercise Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 795420.	2.4	0
2	Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 56.	1.7	0
3	Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry. <i>Respirology</i> , 2022, 27, 517-528.	2.3	15
4	A case report of a long-term survivor after inadvertent ligation of left pulmonary artery during intended ductal ligation. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac127.	0.6	0
5	High Betaine and Dynamic Increase of Betaine Levels Are Both Associated With Poor Prognosis of Patients With Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852009.	2.4	7
6	High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	12
7	Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China. <i>Respirology</i> , 2021, 26, 196-203.	2.3	21
8	Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: a retrospective single-center study in China. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1047-1057.	1.7	3
9	Mildly Elevated Pulmonary Arterial Pressure Is Associated With a High Risk of Progression to Pulmonary Hypertension and Increased Mortality: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e018374.	3.7	11
10	Risk prediction in medically treated chronic thromboembolic pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , 2021, 21, 128.	2.0	5
11	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. <i>Annals of the American Thoracic Society</i> , 2021, 18, 981-988.	3.2	28
12	Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 699904.	2.4	4
13	The Role of Four-Dimensional Automatic Right Ventricular Quantification Technology to Determine RV Function and Hemodynamics in Patients With Pulmonary Hypertension Compared With Right Heart Catheterization. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 628610.	2.4	1
14	Identification of Potential Risk Genes and the Immune Landscape of Idiopathic Pulmonary Arterial Hypertension via Microarray Gene Expression Dataset Reanalysis. <i>Genes</i> , 2021, 12, 125.	2.4	7
15	Endovascular Repair for Patent Ductus Arteriosus-Related Endoleak in Aortic and Pulmonary Artery Dissection Patient. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e327-e329.	2.9	0
16	Diffusing Capacity for Carbon Monoxide Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 762267.	2.4	5
17	Exercise pathophysiology differs between connective tissue diseases-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1063-1070.	0.8	0
18	Prognostic value of hemodynamics and comorbidities in pulmonary hypertension due to advanced heart failure. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 158-164.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Association between splenectomy and portal hypertension in the development of pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	1.7	3
20	Comparison of V/Q SPECT and CT Angiography for the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension. <i>Radiology</i> , 2020, 296, 420-429.	7.3	32
21	Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants. <i>BMC Pulmonary Medicine</i> , 2020, 20, 150.	2.0	6
22	Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110355.	5.6	12
23	Leriche syndrome in a patient with acute pulmonary embolism and acute myocardial infarction: a case report and review of literature. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 26.	1.7	5
24	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. <i>Annals of Nuclear Medicine</i> , 2020, 34, 407-414.	2.2	11
25	Serum human epididymis protein 4 level as a predictor of clinical worsening in idiopathic pulmonary arterial hypertension: a pilot study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 175.	1.7	3
26	Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. <i>Respiratory Research</i> , 2019, 20, 250.	3.6	38
27	Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?. <i>BMC Pulmonary Medicine</i> , 2019, 19, 257.	2.0	6
28	Value of lung perfusion scintigraphy in patients with idiopathic pulmonary arterial hypertension: a patchy pattern to consider. <i>Pulmonary Circulation</i> , 2019, 9, 1-7.	1.7	8
29	Peak circulatory power is a strong prognostic factor in patients with idiopathic pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2018, 135, 29-34.	2.9	10
30	Transgelin as a potential target in the reversibility of pulmonary arterial hypertension secondary to congenital heart disease. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 6249-6261.	3.6	24
31	Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study. <i>Pulmonary Circulation</i> , 2018, 8, 1-12.	1.7	21
32	Genetic analyses in a cohort of 191 pulmonary arterial hypertension patients. <i>Respiratory Research</i> , 2018, 19, 87.	3.6	22
33	Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 43, 26-31.	2.6	8
34	Oxygen Uptake Efficiency Slope Predicts Poor Outcome in Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
35	Quantitative assessment of right ventricular glucose metabolism in idiopathic pulmonary arterial hypertension patients: a longitudinal study. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1161-1168.	1.2	16